FrancesElaineChowMD

Neurology • Los Angeles, CA

Neuro-Oncology

Join to view full profile

Dr. Chow is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Chow's full profile

Already have an account?

Office
1520 San Pablo St
Ste 3800
Los Angeles, CA 90033
Phone+1 323-442-5720

Education & Training

UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Neuro-Oncology, 2018 - 2020
University of Southern California/Los Angeles General Medical Center (USC/LA General)Chief Residency, Neurology, 2017 - 2018
University of Southern California/Los Angeles General Medical Center (USC/LA General)Residency, Neurology, 2015 - 2018
University of California (Irvine)Internship, Transitional Year, 2014 - 2015
Drexel University College of MedicineClass of 2014

Certifications & Licensure

CA State Medical License 2016 - 2025
American Board of Psychiatry and Neurology Neurology
Neurocritical Care SocietyCertification of Emergency Neurological Life Support

Awards, Honors, & Recognition

Top Doctor Los Angeles Magazine, 2022-2024
Southern California Rising Stars Super Doctors®, 2020-2024
Top Doctor Pasadena Magazine, 2022-2023
Outstanding Teaching Award University of Southern California, 2018
Victor M. Victoroff M.D. Award for Compassionate Patient Care in Neurology University of Southern California, 2017
David Dunn M.D. Award for Excellence in Neurology Drexel University College of Medicine, 2014
Join now to see all

Clinical Trials

Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment Start of enrollment: 2023 Mar 20
Suspended
Phase 1, Phase 2
A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma Start of enrollment: 2020 Jun 08
Terminated
Phase 1, Phase 2
Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBM Start of enrollment: 2020 Dec 08
Active, not recruiting
Not Applicable
NEO100 and High-Grade Meningioma Start of enrollment: 2022 Jul 01
Recruiting
Phase 2
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma Start of enrollment: 2016 Apr 08
Recruiting
Phase 1, Phase 2
A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Biomarker, DGM1 Start of enrollment: 2020 Dec 16
Completed
Phase 3
Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations Start of enrollment: 2022 May 20
Active, not recruiting
Phase 2
Nivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Patients With Recurrent Grade II-III Meningioma Start of enrollment: 2019 Jun 17
Recruiting
Phase 1, Phase 2
NovoTTF-200A Device in Treating Patients With Newly Diagnosed High Risk Oligodendroglioma Start of enrollment: 2017 Dec 15
Withdrawn
Not Applicable
Precise DCE-MRI in Diagnosing Participants With Recurrent High Grade Glioma or Melanoma Brain Metastases Start of enrollment: 2021 Apr 13
Terminated
Not Applicable
Standard Chemotherapy vs. Chemotherapy Guided by Cancer Stem Cell Test in Recurrent Glioblastoma Start of enrollment: 2018 May 20
Completed
Phase 3
Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM) Start of enrollment: 2023 Sep 15
Recruiting
Phase 2, Phase 3
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Incidence of brain metastasis according to patient race and primary cancer origin: a systematic review.
David Gomez, Jeffrey J Feng, Stephanie Cheok, Ishan Shah, Holly Dicharry
Journal of Neuro-Oncology. 2024-09-01
5 citations
Genome-wide loss of heterozygosity predicts aggressive, treatment-refractory behavior in pituitary neuroendocrine tumors.
Andrew L Lin, Vasilisa A Rudneva, Allison L Richards, Yanming Zhang, Hyung Jun Woo
Acta Neuropathologica. 2024-05-17
6 citations
Multi-omic profiling reveals discrepant immunogenic properties and a unique tumor microenvironment among melanoma brain metastases.
Gino K In, Jennifer R Ribeiro, Jun Yin, Joanne Xiu, Matias A Bustos
NPJ Precision Oncology. 2023-11-14

Journal Articles

The Challenge of Distinguishing POEMS from CIDP: Importance of Early Recognition and Diagnosis of POEMS
Chow F, Darki L, Beydoun SR, US Neurology, 7/30/2018

Abstracts/Posters

Single-cell RNAseq of tumor infiltrating immune cells from neoadjuvant anti-PD1 treated GBM patients reveals global transcriptional changes and immunosuppressive adap...
Lee A, Mochizuki A, Chow F, Reynoso J, Orpilla J, Sun L, Chavez C, Galvez M, Kienzler J, Yong W, Everson R, Nathanson D, Bensinger S, Liau L, Cloughesy TF, Hugo W, Pri..., Neuro-Oncology, 11/2020
Neoadjuvant PD-1 antibody blockade remodels the immune microenvironment of metastatic brain tumors
Sun L, Kienzler J, Lee A, Chow F, Chavez C, Yong W, Everson R, Kim W, Hugo W, Prins RM, Neuro-Oncology, 11/2020
Validation of Response to Neoadjuvant Anti-PD-1 immunotherapy in Recurrent Glioblastoma
Chow F, Mochizuki A, Lee A, Galvez M, Orpilla JR, Everson RG, Liau LM, Cloughesy TF, Prins RM, Neuro-Oncology, 11/11/2019
Myeloid Populations and the Effect of Neoadjuvant PD-1 Inhibition in the Glioblastoma Microenvironment: a Surfaceomic and Transcriptomic Dissection at the Single-Cell ...
Mochizuki A, Lee A, Orpilla J, Kienzler J, Galvez M, Chow F, Davidson T, Wang A, Everson R, Liau L, Cloughesy T, Prins R, Neuro-Oncology, 11/11/2019
Neoantigens Arising from Alternative Splicing Events May be Targeted by Tumor Infiltrating Lymphocytes in Glioblastoma
Lee A, Pan Y, Mochizuki A, Galvez M, Chow F, Nathanson D, Wang A, Everson R, Liau L, Xing Y, Prins R, Neuro-Oncology, 11/11/2019
Neurosimulation as an Educational Tool for the Management of ICP Crisis: Effective, Understudied and Underutilized
Poblete R, Chow F, Sung G, Sanossian N, Neurocritical Care Society, 9/26/2018
Medical Simulation as the Standard for Acute Stroke Education: Review of the Literature and Recommendations for Future Implementation
Chow F, Sanossian N, Sung G, Poblete R, Neurology, 4/9/2018
The Pathological Role of Isomerase PTPA at Synapses in Alzheimer’s Disease
Gong Y, Chow F, Lippa CF, Society of Neuroscience, 11/13/2016
Peptidyl-Prolyl Isomerase Pin1 as a Potential Target to Protect Synaptic Function in Preclinical Alzheimer's Disease
Ong E, Chow F, Gong Y, Lippa CF, Neurology, 4/9/2014
Pathogenic Role of Pin1 in Synaptic Dysfunction in Alzheimer’s Disease
Chow F, Lippa CF, Gong Y, Alzheimer's & Dementia, 7/2013
Bevacizumab Treatment in Glioblastoma Patients is Associated with an Increased Development of Secondary Gliosarcoma
Yang I, Spasic M, Chow F, Choy W, Nghiemphu PL, Cloughesy T, Liau LM, Lai A, Neurosurgery, 8/2012
Peptidyl-Prolyl Isomerase Pin1: A Common Therapeutic Target for Synaptic Dysfunction and Protein Misfolding in Alzheimer's Disease
Chow F, Tsai R, Lippa CF, Gong Y, Neurology, 4/1/2012
Join now to see all